Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SVB Leerink Adjusts BridgeBio Pharma's Price Target to $66 from $68, Keeps Outperform Rating

11/19/2021 | 08:46am EST


ę MT Newswires 2021
All news about BRIDGEBIO PHARMA, INC.
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
DJ
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
MT
01/13BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially B..
GL
01/10BRIDGEBIO PHARMA : Corporate Presentation January 2022
PU
01/06SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bridg..
PR
01/05UBS Adjusts BridgeBio Pharma PT to $30 From $80, Maintains Buy Rating
MT
01/05BRIDGEBIO PHARMA : Corporate Presentation January 2022
PU
01/04INSIDER BUY : Bridgebio Pharma
MT
2021Alnylam Pharmaceuticals' Onpattro in 'Relatively Strong Position' to Succeed Despite Br..
MT
2021HC Wainwright Adjusts BridgeBio Pharma's Price Target to $24 From $88, Reiterates Buy R..
MT
More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 78,3 M - -
Net income 2021 -534 M - -
Net Debt 2021 336 M - -
P/E ratio 2021 -3,43x
Yield 2021 -
Capitalization 1 877 M 1 877 M -
EV / Sales 2021 28,3x
EV / Sales 2022 33,2x
Nbr of Employees 391
Free-Float -
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | BBIO | US10806X1028 | MarketScreener
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 12,75 $
Average target price 27,40 $
Spread / Average Target 115%
EPS Revisions
Managers and Directors
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BRIDGEBIO PHARMA, INC.-23.56%1 877
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317